Vivos Therapeutics (VVOS) Cash from Operations (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of Cash from Operations data on file, last reported at 6010000.0 in Q1 2026.

• Cash from Operations for Q1 2026 came in at 6010000.0, down 58.32% year-over-year; the trailing twelve-month figure through Mar 2026 was 17477000.0 (down 25.09% YoY), and the FY2025 annual result was 15263000.0, down 20.27% from the prior year.
• Cash from Operations retreated to 6010000.0 in Q1 2026 per VVOS's latest filing, from 3763000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 2516000.0 in Q1 2024 and troughed at 6100000.0 in Q1 2022.
• A 5-year average of 3850058.82 and a median of 3504000.0 in 2025 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2023 and 2026: Cash from Operations surged 52.54% in 2023, then sank 58.32% in 2026.
• A 5-year view of Cash from Operations shows it stood at 2987000.0 in 2022, then climbed by 9.61% to 2700000.0 in 2023, then declined by 8.89% to 2940000.0 in 2024, then dropped by 27.99% to 3763000.0 in 2025, then plunged by 59.71% to 6010000.0 in 2026.
• Business Quant data shows VVOS's Cash from Operations at 6010000.0 in Q1 2026, 3763000.0 in Q4 2025, and 4200000.0 in Q3 2025.